Gupta Mahima, Shailaja S, Hegde K Sudhir
Resident, Department of Anaesthesiology, Father Muller Medical College , Mangalore, India .
Assistant Professor, Department of Anaesthesiology, Father Muller Medical College , Mangalore, India .
J Clin Diagn Res. 2014 Feb;8(2):114-7. doi: 10.7860/JCDR/2014/7883.4023. Epub 2014 Feb 3.
The supplementation of local anaesthetics with adjuvants to improve the efficacy of subarachnoid block has been recognised since long. The most preferred drug has been opioids, but newer drugs like dexmedetomidine has also been introduced and investigated as an effective adjuvant.
This study was conducted to evaluate and compare the characteristics of subarachnoid blockade, hemodynamic stability and adverse effects of intrathecal buprenorphine and intrathecal dexmedetomidine as an adjuvant to 0.5% hyperbaric bupivacaine for lower abdominal surgeries.
The present study included 60 patients aged between 18-60 years classified as American Society of Anesthesiologists (ASA) Physical Status (PS) I/II scheduled for elective lower abdominal surgeries. The patients were randomly allotted to two groups to receive intrathecal 3ml of 0.5% bupivacine with 60µg of buprenorphine (Group B; n=30) or 3ml of 0.5% bupivacaine with 5µg of dexmedetomidine (Group D; n=30). The onset time to peak sensory level, motor block, sedation, Haemodynamic variables, duration of motor block, analgesia and any adverse effects were noted.
There was no significant difference between groups regarding demographic characteristics and type of surgery. The motor, sensory blockade and time of rescue analgesia were significantly prolonged in Group D compared to Group B. The sedation level was higher in Group D compared to Group B. There was no significant difference in haemodynamic variables although Group B had lower Heart Rate (HR) than Group D.
Intrathecal dexmedetomidine when compared to intrathecal buprenorphine causes prolonged anaesthesia and analgesia with reduced need for sedation and rescue analgesics.
长期以来,人们一直认识到在局部麻醉药中添加佐剂可提高蛛网膜下腔阻滞的效果。最常用的药物是阿片类药物,但像右美托咪定这样的新药也已被引入并作为一种有效的佐剂进行研究。
本研究旨在评估和比较鞘内注射丁丙诺啡和鞘内注射右美托咪定作为0.5%重比重布比卡因辅助药物用于下腹部手术时蛛网膜下腔阻滞的特点、血流动力学稳定性及不良反应。
本研究纳入60例年龄在18至60岁之间、美国麻醉医师协会(ASA)身体状况(PS)为I/II级、计划进行择期下腹部手术的患者。患者被随机分为两组,分别接受鞘内注射3ml含60μg丁丙诺啡的0.5%布比卡因(B组;n = 30)或3ml含5μg右美托咪定的0.5%布比卡因(D组;n = 30)。记录达到最高感觉平面的起效时间、运动阻滞、镇静情况、血流动力学变量、运动阻滞持续时间、镇痛效果及任何不良反应。
两组在人口统计学特征和手术类型方面无显著差异。与B组相比,D组的运动、感觉阻滞及补救镇痛时间显著延长。D组的镇静水平高于B组。尽管B组心率低于D组,但血流动力学变量无显著差异。
与鞘内注射丁丙诺啡相比,鞘内注射右美托咪定可导致更长时间的麻醉和镇痛,同时减少对镇静和补救镇痛药的需求。